Teladoc Health Q1 2024 Adj EPS $(0.49) Misses $(0.46) Estimate, Sales $646.10M Beat $637.29M Estimate
Portfolio Pulse from Benzinga Newsdesk
Teladoc Health reported Q1 2024 adjusted EPS of $(0.49), missing the $(0.46) estimate, but sales of $646.10M exceeded the $637.29M forecast, marking a 2.68% year-over-year increase.
April 25, 2024 | 8:06 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Teladoc Health's Q1 2024 earnings report showed a miss on adjusted EPS but exceeded sales expectations with a 2.68% YOY growth.
The miss on the EPS estimate could negatively impact investor sentiment in the short term, but the beat on sales forecasts and the year-over-year growth might offset this by indicating operational strength and potential for future profitability. The mixed results present a neutral outlook in the short term as investors weigh the implications of the earnings miss against the sales beat.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100